Not recruiting
Respiratory syncytial virus infection+3
Not recruitingStudy on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections
Registered drugNo placebo
Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections
Registered drugNo placebo
- Disease:Respiratory syncytial virus infectionRespiratory syncytial virus bronchiolitis+2
- Substances:–
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years · Healthy volunteers
- Sponsor:GlaxoSmithKline Biologicals



